Term
|
Definition
| increases cGMP production which relaxes vascular smooth muscle |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Competitive inhibition of HMG CoA Reductase |
|
|
Term
|
Definition
| Decreased plasma LDL levels, decreased vascular inflammation, improved endothelial cell function |
|
|
Term
|
Definition
| hepatotoxicity (serum aminotransferase), skeletal myopathy (serum creatine kinase), teratogen (avoid during pregnancy) |
|
|
Term
|
Definition
| metabolized by CYP3A4 or CYP2C9; potential drug interactions (warfarin) |
|
|
Term
|
Definition
| CAD (primary and secondary prevention) |
|
|
Term
|
Definition
| Cyclooxygenase (COX-1) in platelets |
|
|
Term
| Aspirin: mechanism of action |
|
Definition
| irreversible acetylation of enzyme at active site |
|
|
Term
|
Definition
| reduced synthesis of thromboxane A2 |
|
|
Term
|
Definition
| hypersensitivity (aspirin induced asthma), slightly prolonged bleeding time |
|
|
Term
|
Definition
| oral administration, renal excretion |
|
|
Term
|
Definition
| antithrombotic effect in patients at risk for CAD |
|
|
